Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of GeneDx ...

Integration streamlines the implementation process and enhances the clarity and accessibility of results within the EHR, UNC ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

Grizzly Research is short GeneDx (WGS), saying insiders attest that the company is “actively committing widespread fraud.” In a recently ...

In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a ...

The research firm’s target, released on Jan. 7, indicates shares could still rise by 51%. Below, I’ll detail what GeneDx’s products are and how the company makes money. I’ll also break ...

The research firm’s target, released on Jan. 7, indicates shares could still rise by 51%. Below, I’ll detail what GeneDx’s products are and how the company makes money. I’ll also break down its ...

If you want to know who really controls GeneDx Holdings Corp. (NASDAQ:WGS), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...